Estamos no ar no ! Saiba mais

AbbVie

ABBV

Valor de mercado US$ 504 bi

285,42 USD

+2,02

0,71%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

286,88

+1,46

0,51%

1 dia

0,71%

5 dias

2,8%

1 mês

8,73%

3 meses

12,2%

6 meses

36,57%

No acumulado do ano

24,47%

1 ano

25,81%

5 anos

165,68%

10 anos

374,59%

Sobre: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Funcionários: 57.000

Saúde Fabricantes de medicamentos — geral

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 55,7%

Neutro 37%

Negativo 7,3%

The Motley Fool

Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends

AbbVie is a resilient Dividend King with a wide moat. It still looks cheap relative to its long-term growth potential.

Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

The Motley Fool

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie's newer drugs are growing fast enough to more than replace Humira revenue. The hardest part of the transition appears to be behind it.

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Zacks Investment Research

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?

Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?

Zacks Investment Research

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

24/7 Wall Street

Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying

Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway.

Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying

The Motley Fool

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie is aggressively diversifying its pipeline to mitigate the revenue impact from its loss of patent exclusivity on Humira. Novo Nordisk maintains a dominant lead in the rapidly expanding metabolic health market through its blockbuster obesity treatments.

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

24/7 Wall Street

5 High-Yield Dividend Stocks That Could Turn October's Market Weakness Into Income

Two of these five dividend stocks just took a beating in October, and that selloff quietly pushed their yields to levels that make the safer-looking names on the list look stingy by comparison.

5 High-Yield Dividend Stocks That Could Turn October's Market Weakness Into Income

Netflix, DocuSign And A Health Care Stock On CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, picked Netflix, Inc. (NASDAQ:NFLX).

Netflix, DocuSign And A Health Care Stock On CNBC's ‘Final Trades'

The Motley Fool

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie continues to diversify its portfolio through the successful expansion of newer therapies like Skyrizi and Rinvoq. Eli Lilly and has seen explosive growth driven by its dominant presence in the massive cardiometabolic treatment market.

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™